Use of cookies

Lund University uses cookies to ensure that the website functions properly and to improve your experience.

Read more in our cookie policy

Search results

Filter

Reset filter

Filetype

Your search for "credit fc 26 pc Visitez le site Buyfc26coins.com Service de qualité pour mes besoins en FC 26 coins.wohu" yielded 41636 hits

Generell recepthanterare för processindustri

Prevas has in its customer contracts had a need for a simpler general manager for process recipes which send recipe parameters (eg rotational speed of a mixer or temperature in a furnace, etc.) to a Programmable Logic Controller. Software for this is available on the market but are either too complex or costly. To solve this problem a Windows service was developed. This report briefly describes ho

Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

Primary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder associated with autosomal recessive variants in genes required for perforin-mediated lymphocyte cytotoxicity. A rapid diagnosis is crucial for successful treatment. Although defective cytotoxic T lymphocyte (CTL) function causes pathogenesis, quantification of natural killer (NK)–cell exocytosis triggered by K562 targe

Potentialities of manganese ore and iron-carbon particles for pharmaceuticals and personal care products removal in electroactive constructed wetland

This study explores the use of manganese ore, iron-carbon particles (Fe-C), and gravel as anode fillers in electroactive constructed wetlands (ECWs) to treat wastewater containing pharmaceuticals and personal care products (PPCPs) including ciprofloxacin (CIP), ofloxacin (OFL), and naproxen (NPX), while also assessing bioelectricity production. Although the presence of PPCPs reduced pollutant remo

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

Background: Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its safety and efficacy in patients with relapsed/refractory follicular lymphoma (FL) after prior rituximab therapy. Design and methods: Forty-seven patients were treated in three dose cohorts and received eight infusions every 3